Nuclear factor erythroid 2–related factor 2 and β‐Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications-Reference-Cited by-同舟云学术

Nuclear factor erythroid 2–related factor 2 and β‐Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications

Published:2021-06-21 Issue:2 Volume:74 Page:741-759
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Tao Junyan¹²,Krutsenko Yekaterina¹²,Moghe Akshata²³,Singh Sucha¹²,Poddar Minakshi¹²,Bell Aaron¹²,Oertel Michael¹²,Singhi Aatur D.¹²,Geller David²⁴,Chen Xin⁵^ORCID,Lujambio Amaia⁶^ORCID,Liu Silvia¹²,Monga Satdarshan P.¹²³^ORCID

Affiliation:

1. Department of Pathology University of PittsburghSchool of Medicine and University of Pittsburgh Medical Center Pittsburgh PA

2. Pittsburgh Liver Research Center University of PittsburghSchool of Medicine and University of Pittsburgh Medical Center Pittsburgh PA

3. Department of Medicine University of PittsburghSchool of Medicine and University of Pittsburgh Medical Center Pittsburgh PA

4. Department of Surgery University of PittsburghSchool of Medicine and University of Pittsburgh Medical Center Pittsburgh PA

5. Department of Bioengineering and Therapeutic Sciences and Liver Center University California San Francisco CA

6. Department of Oncological Sciences Tisch Cancer Institute Precision Immunology Institute, and Liver Cancer Program Icahn School of Medicine at Mount Sinai New York NY

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Cancer Institute

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31730

Reference43 articles.

1. Burden of liver diseases in the world

2. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma